JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Videla, S.
Right arrow Articles by Malagelada, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Videla, S.
Right arrow Articles by Malagelada, J. R.

Vol. 287, Issue 3, 854-859, December 1998

Antitumor Necrosis Factor Therapy in Rat Chronic Granulomatous Colitis: Critical Dose-Timing Effects on Outcome1

Sebastián Videla, Ana García-Lafuente, María Antolín, Jaime Vilaseca, Francisco Guarner, Ernesto Crespo, Guadalupe González, Antonio Salas and Juan R. Malagelada

Digestive System Research Unit (S.V., A.G.-L., M.A., J.V., F.G., J.R.M.) and Department of Microbiology (E.C.), Hospital General Vall d'Hebron, Department of Pathology (G.G., A.S.), Barcelona, Spain

Inhibition of tumor necrosis fact (TNFalpha ) is of potential benefit in the treatment of chronic inflammatory conditions. However, TNFalpha plays an important role in host defenses against infection, and blocking TNFalpha production may also have adverse effects. We tested the efficacy and safety of anti-TNFalpha therapy in experimental colitis induced by trinitrobenzenesulfonic acid. We cultured colonic wall specimens for bacterial growth and measured native TNFalpha protein synthesis in colonic tissue at days 0, 1, 4, 10 and 18 after induction of colitis. Anti-TNFalpha therapy (monoclonal g1 immunoglobulin, 15 mg/kg i.p., every third day) was started on either day 4 or day 10 after induction of colitis. On day 18, we measured the release of inflammatory mediators and scored colonic lesions. In acute lesions, several species of the common flora were grown, including Streptococcus, Staphylococcus, Bacteroides, clostridia and enterobacteria. In chronic lesions, only enterobacteria, clostridia and lactobacilli were isolated. TNFalpha production by inflamed colonic tissue was increased in both acute and chronic lesions. Anti-TNFalpha therapy induced a significant decrease in the release of inflammatory mediators and histopathological remission when treatment started on day 10. However, anti-TNFalpha therapy increased eicosanoid release and lesion scores when treatment started on day 4. In conclusion, acute colonic lesions showed polymicrobial infection. Anti-TNFalpha therapy induced remission of chronic intestinal inflammation, but early treatment did not prove effective.


0022-3565/98/2873-0854$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
C. Medina, A. Santana, M. C. Paz, F. Diaz-Gonzalez, E. Farre, A. Salas, M. W. Radomski, and E. Quintero
Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis
J. Leukoc. Biol., May 1, 2006; 79(5): 954 - 962.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Videla, J. Vilaseca, C. Medina, M. Mourelle, F. Guarner, A. Salas, and J.-R. Malagelada
Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 940 - 945.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. J. Myers, S. Murthy, A. Flanigan, D. R. Witchell, M. Butler, S. Murray, A. Siwkowski, D. Goodfellow, K. Madsen, and B. Baker
Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-alpha in Two Murine Models of Colitis
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 411 - 424.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
R Boismenu, Y Chen, K Chou, A El-Sheikh, and R Buelow
Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis
Ann Rheum Dis, November 1, 2002; 61(90002): ii19 - 24.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.